Clay Siegall cofounded Seattle Genetics in 1988 and is currently the President, CEO and a sits on the company’s board as a member of its directors. The company leads in innovation in antibodies technology and has made a drug; an antibody conjugate known as ADC. Dr. Siegall has led Seattle Genetics’ capital raising campaign, helping the company amass funds amounting to over US $330 million via private and public financing taking into account the firm’s 2001 initial public offering. Seattle Genetics has as well made deals with several key organizations, for instance, the company has entered into an $860 million deal for SGN-40 with Genentech, Bayer, and Progenics, CuraGen, and MedImmune. Since 2001, the company’s involvement with the named companies has raised about 65 million dollars.

Education and Work Experience

Before he cofounded Seattle Genetics, Clay Siegall worked for National Institutes of Health and the National Cancer Institute from 1988-1991. From 1991 to 1997, Dr. Siegall used to work for the Bristol-Myers Squibb Pharmaceutical Research Institute. He has a Bachelor of Science degree in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. He serves on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance, the Washington Biotechnology and Biomedical Association (WBBA) as well as the Alder Biopharmaceuticals’ Board of Directors.

Fight against Cancer

Seattle Genetics is targeting different strains of autoimmune and cancer symptoms using its many assortments of experimental cancer drugs it’s developing. At the moment, Seattle Genetics is developing more than ten cancer drugs. One of these drugs which go by 33A will be used to treat acute myeloid leukemia, and it is in the third stage of clinical analysis. The company has also reported that it is in the final stages of development of a breast and bladder cancer drugs. Also, Seattle Genetics is conducting innovative clinical research for a Hodgkin lymphoma drug called Adcetris. The drug will be used to treat the condition if detected in its early stages. Previously, there was no cure for Hodgkin lymphoma whatsoever.

Journalists at Pacific Northwest Research Institute Newsroom describes meeting Dr. Clay Siegall as a one of a kind ‘learning’ experience.

Learn more about Clay Siegall:

https://www.crunchbase.com/person/clay-b-siegall#/entity

http://www.xconomy.com/author/csiegall/

Categories: Leader

Comments are Closed on this Post